Acura is established in July 2017. Acura was established by a scientist team with biomedical, chemical, drug research and development and Nammiological expertise. By integrating key technologies in a variety of fields, the AN-845 and NaM injection type NANO-845 and ACGEL-845 were successfully developed, and the ACGEL-845 was labeled in living animal experiments, and the AN-845 can completely inhibit resistance. Growth of pancreas cancer tumors. The experiment also also showed an AN-845 for a variety of cancers such as cerebral cancer (GBM), hepatocellular carcinoma, HCC), milk cancer (TNBC) ....